Another drug used to treat myelofibrosis and treatment‐resistant PV is Ruxolitinib, an inhibitor of Janus‐associated kinases (JAK1 and JAK2) (Kim et al., 2021). This evidence concerns the gene JAK2 and acquired polycythemia vera.